文献速递妇科

阿培利司治疗PIK3CA突变晚期妇科肿瘤:临床活性的初步线索

Alpelisib for PIK3CA-mutated advanced gynecological cancers: First clues of clinical activity.
PubMed 文献 · Gynecol Oncol · 2024-03-21

在2021年4月至2022年12月的前瞻性管理项目中,36例PIK3CA突变晚期妇科肿瘤患者接受阿培利司300 mg每日一次口服,客观缓解率为28%、疾病控制率为61%,子宫内膜癌患者获益最大(分别为35%和71%)。作者认为阿培利司是此类复发肿瘤的活性治疗选择,并支持开展生物标志物驱动的随机试验。

要点

  • 36例PIK3CA突变晚期妇科肿瘤患者接受阿培利司300 mg每日一次口服,客观缓解率28%、疾病控制率61%。
  • 子宫内膜癌患者获益最大,客观缓解率35%、疾病控制率71%。
  • 作者认为阿培利司是PIK3CA突变复发妇科肿瘤的活性治疗选择。

核心结论

  • 阿培利司是携带PIK3CA突变的复发性妇科肿瘤患者的活性治疗选择。
  • 这些发现支持在妇科肿瘤中开展生物标志物驱动的PI3K抑制剂随机试验。

研究设计与样本

  • 2021年4月至2022年12月,36例PIK3CA突变晚期妇科肿瘤患者在一个受控项目中前瞻性接受阿培利司300 mg每日一次口服治疗。
  • 研究主要目标为客观缓解率和疾病控制率所反映的抗肿瘤活性。

主要发现

  • 纳入患者中子宫内膜癌17/36例(47%)、卵巢癌10/36例(28%)、其他妇科肿瘤9/36例(25%)。
  • 多数患者既往接受过2–3线全身治疗(子宫内膜癌47.2%、卵巢癌60%、其他56%),基线时存在内脏转移(分别为82%、70%、56%)。
  • 共发现17种不同的PIK3CA突变,其中53%位于激酶结构域(最常见为H1047R),36%位于螺旋结构域(最常见为E545K)。
  • 总体客观缓解率为28%,疾病控制率为61%;子宫内膜癌患者获益最大,客观缓解率35%、疾病控制率71%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Recurrent gynecological tumors (e.g., endometrial, and ovarian cancers) are incurable diseases; therefore, new treatment options are urgently needed. The PTEN-AKT-PI3K pathway is frequently altered in these tumors, representing a potential treatment target. Alpelisib is an α-specific PI3K inhibitor approved in PIK3CA-mutated advanced breast cancer. We report outcomes from a large series of patients with PIK3CA-mutated gynecological cancers prospectively treated with alpelisib within a controlled program. METHODS: From April 2021 to December 2022, 36 patients with PIK3CA-mutated advanced gynecological cancers received alpelisib 300 mg orally once daily. Objective response (ORR) and disease control (DCR) rates provided measure of the antitumor activity of alpelisib, the primary objective of the study. RESULTS: Included patients had endometrial (17/36 [47%]), ovarian (10/36 [28%]), or other gynecological cancers (9/36 [25%]). Most patients had received 2-3 prior systemic treatments (endometrial, 47·2%; ovarian, 60%; other, 56%), and presented with visceral metastases at baseline (82%, 70%, and 56%, respectively). Overall, 17 different PIK3CA mutations were found, including 53% in the kinase domain (most commonly H1047R) and 36% in the helical domain (most commonly E545K). Overall, the ORR was 28% and DCR was 61%, with the greatest benefit observed in patients with endometrial cancer (35% and 71%, respectively). CONCLUSION: Alpelisib represents an active treatment option in patients with recurrent gynecological cancers harboring a PIK3CA mutation. These findings support the need of biomarker-driven randomized trials of PI3K inhibitors in gynecological cancers.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Passarelli A, Carbone V, Pignata S, et al. Alpelisib for PIK3CA-mutated advanced gynecological cancers: First clues of clinical activity. Gynecol Oncol. 2024. PMID: 38518529. doi:10.1016/j.ygyno.2024.02.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。